Cargando…
Epigenetic modulation in sensitizing metastatic sarcomas to therapies and overcoming resistance
Sarcomas are a class of rare malignancies of mesenchymal origin with a heterogeneous histological spectrum. They are classically associated with poor outcomes, especially once metastasized. A path to improving clinical outcomes may be made through modifying the epigenome, where a variety of sarcomas...
Autores principales: | Rytlewski, Jeff, Brockman, Qierra R., Dodd, Rebecca D., Milhem, Mohammed, Monga, Varun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992584/ https://www.ncbi.nlm.nih.gov/pubmed/35582536 http://dx.doi.org/10.20517/cdr.2021.88 |
Ejemplares similares
-
Turning ‘Cold’ tumors ‘Hot’: immunotherapies in sarcoma
por: Rytlewski, Jeff, et al.
Publicado: (2021) -
Photodynamic Therapy Using Hippo Pathway Inhibitor Verteporfin: A Potential Dual Mechanistic Approach in Treatment of Soft Tissue Sarcomas
por: Rytlewski, Jeffrey D., et al.
Publicado: (2021) -
Augmenting chemotherapy with low-dose decitabine through an immune-independent mechanism
por: Gutierrez, Wade R., et al.
Publicado: (2022) -
Patient reported quality of life in young adults with sarcoma receiving care at a sarcoma center
por: Day, Jonathan R., et al.
Publicado: (2022) -
Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study
por: Zakharia, Yousef, et al.
Publicado: (2017)